医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Courtagen Initiates Partnership with Pronto Diagnostics and Medica Labs for Distribution of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders

2015年04月23日 PM08:43
このエントリーをはてなブックマークに追加


 

WOBURN, Mass.

Courtagen Life Sciences, Inc., an innovative molecular information company, announced today international distribution agreements with Pronto Diagnostics Ltd., headquartered in Tel Aviv, Israel, and Medica Labs, headquartered in Bangkok, Thailand. Courtagen continues to expand its international presence, and is pursuing similar commercial relationships with leading distributors in markets around the world.

Often diagnosis of pediatric neurological and metabolic disorders is challenging due to the wide range of symptoms and severity, and frequently genetic factors play a pivotal role. Courtagen’s genetic tests take advantage of recent advances in Next Generation Sequencing technology, and enable new opportunities to find genetic causes of disorders such as epilepsy, mitochondrial disorders, developmental delay, and lysosomal storage disorders to guide treatment to improve the patient’s quality of life.

“Pronto Diagnostics, a leader in the Israeli genetic testing market, is proud to add Courtagen’s unique assays to its portfolio. Pronto offers genetic testing services to all of the Israeli healthcare providers and this new addition aligns with the company’s strategy of presenting the local market with the world’s leading tests in specific clinical fields,” said Nir Navot, President of Pronto Diagnostics. “We expect that local clinicians will embrace this technology and improve the care of their patients.”

“We are enthusiastic to work together with Pronto Diagnostics and Medica Labs in expanding our global presence,” said Mike Catalano, Courtagen’s Sr. Director of Business Development. “As leaders in their respective markets, we look forward to harnessing their expertise and making Courtagen’s advanced clinical tests available to more physicians in more places around the world.”

About Courtagen Life Sciences, Inc.

Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.

CONTACT

Courtagen Life Sciences, Inc.
Mike Catalano, 877-395-7608
mike.catalano@courtagen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc